Candel Therapeutics (NASDAQ:CADL – Get Free Report) is expected to issue its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Candel Therapeutics to post earnings of ($0.3372) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.28). On average, analysts expect Candel Therapeutics to post ($1.29) EPS for the current fiscal year and ($1.27) EPS for the next fiscal year.
Candel Therapeutics Stock Up 2.6%
CADL opened at $9.05 on Thursday. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38. The stock has a market cap of $692.51 million, a price-to-earnings ratio of -6.42 and a beta of -0.27. Candel Therapeutics has a twelve month low of $4.35 and a twelve month high of $14.00. The company’s 50-day moving average price is $10.41 and its two-hundred day moving average price is $8.31.
Insiders Place Their Bets
In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $12.00, for a total value of $84,000.00. Following the transaction, the chief technology officer directly owned 76,865 shares in the company, valued at $922,380. This represents a 8.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.30% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several brokerages have recently issued reports on CADL. UBS Group restated a “buy” rating on shares of Candel Therapeutics in a research note on Monday, August 17th. Jefferies Financial Group started coverage on Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 price objective on the stock. Zacks Research downgraded Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. HC Wainwright reissued a “buy” rating on shares of Candel Therapeutics in a report on Friday, October 2nd. Finally, Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.43.
Check Out Our Latest Research Report on Candel Therapeutics
Candel Therapeutics Company Profile
Candel Therapeutics, Inc is a clinical-stage biopharmaceutical company developing biological immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach uses engineered viral therapies intended to promote immunogenic cell death and generate broader, potentially systemic antitumor immune responses.
Candel’s pipeline includes CAN-3110, an investigational oncolytic immunotherapy based on a genetically engineered herpes simplex virus type 1.
Featured Stories
- Five stocks we like better than Candel Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
